Prognostic and clinicopathological value of melanoma-associated antigen D4 in patients with glioma

The aim of the present study was to evaluate the clinical importance of melanoma-associated antigen D4 (MAGE-D4) expression in glioma, and to identify it as a valuable prognostic biomarker and therapeutic target. To achieve this, the expression of MAGE-D4 protein in 124 tumor tissues from patients w...

Full description

Saved in:
Bibliographic Details
Published in:Oncology letters 2018-04, Vol.15 (4), p.4151-4160
Main Authors: Yan, Jun, Wen, Jing, Wei, Zong-Dang, Li, Xi-Sheng, Li, Ping, Xiao, Shao-Wen
Format: Article
Language:English
Subjects:
Age
Antigens
Cancer research
Cancer therapies
Care and treatment
Chemotherapy
Classification
Development and progression
Females
Gene expression
Glioma
Gliomas
Health aspects
Medical prognosis
Melanoma
Metastasis
Multivariate analysis
Nervous system
Oncology
Patients
Prognosis
Protein expression
Proteins
Radiation therapy
Studies
Survival analysis
Tumor antigens
Tumor markers
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of the present study was to evaluate the clinical importance of melanoma-associated antigen D4 (MAGE-D4) expression in glioma, and to identify it as a valuable prognostic biomarker and therapeutic target. To achieve this, the expression of MAGE-D4 protein in 124 tumor tissues from patients with glioma was measured using reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and immunohistochemistry (IHC), and the associations between MAGE-D4expression and clinicopathological factors were evaluated. The survival analysis demonstrated the significant prognostic value of MAGE-D4 in glioma using follow-up data. RT-qPCR and IHC analysis confirmed that MAGE-D4 mRNA and protein expression levels were significantly increased in glioma tissues compared with those in normal brain tissues. The present study demonstrated that the percentage of glioma tissues with high expression of MAGE-D4 mRNA was 67.74%, and the percentage positive for MAGE-D4 protein expression was 78.23%. All patients with high MAGE-D4 expression in cancerous tissues experienced significantly reduced median overall survival (OS; 18.00 vs. 33.29 months; P
ISSN:1792-1074
1792-1082
DOI:10.3892/ol.2018.7884